Just a month after we upgraded Acrux, the Financial Review has published the case for selling

Intelligent Investor

Independent Financial Research

Just a month after we upgraded Acrux, the Financial Review has published the case for selling. That's despite the most recent research finding testosterone replacement therapy (TRT) is safer than earlier studies suggested. Acrux's share price has more than halved since the unfavourable studies triggered an investigation by the US Food and Drug Administration (FDA) in February, with a decision expected early next year. The bear case centres on three main points: (1) growth for testosterone replacement therapies is slowing; (2) competition from generic and new products is increasing; and (3) Acrux's main product, Axiron, is an inferior treatment. Let's examine each claim in turn. (VIEW LINK)


Intelligent Investor
Independent Financial Research

Intelligent Investor is an independent financial research service with a 14-year history of beating the market. Our value investing approach empowers Australians to make more informed decisions to build their long-term wealth. We off structural...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.